Validation of a method for accurate and highly reproducible quantification of brain dopamine transporter SPECT studies

Journal of Nuclear Medicine Technology

Volumn 39, Issue 4, 2011, Pages 271-278

  Jensen, Peter S ^a   Ziebell, Morten ^a   Skouboe, Glenna ^a   Khalid, Usman ^a   de Nijs, Robin ^a   Thomsen, Gerda ^a   Knudsen, Gitte M ^a   Svarer, Claus ^a  

^a University of Copenhagen   (Denmark)

Author keywords

Automatic ROI delineation; Brain imaging; Dopamine transporter; Quantification; SPECT

Indexed keywords

DOPAMINE TRANSPORTER; N(3 IODOPROP2E ENYL) 2 BETA DEXTRO CARBOMETHOXY 3BETA (4 METHYLPHENYL); RADIOLIGAND; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; COMPUTER PROGRAM; CORPUS STRIATUM; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE RECONSTRUCTION; MALE; PROTEIN DETERMINATION; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEADY STATE; VALIDATION STUDY;

AGED; AGED, 80 AND OVER; ALGORITHMS; BRAIN; COMPUTER SIMULATION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MIDDLE AGED; MODELS, NEUROLOGICAL; NORTROPANES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84855610732     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnmt.111.090324     Document Type: Article

References (25)

1. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;20:415-455.
2. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse. 1991;9:43-49.
3. Allard PO, Rinne J, Marcusson JO. Dopamine uptake sites in Parkinson's disease and in dementia of the Alzheimer type. Brain Res. 1994;637:262-266.
4. Bao SY, Wu JC, Luo WF, Fang P, Liu ZL, Tang J. Imaging of dopamine transporters with technetium-99m TRODAT-1 and single photon emission computed tomography. J Neuroimaging. 2000;10:200-203.
5. 123I] beta-CIT and SPECT: correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl. 1997;50:9-24.
6. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA. 1993;90:11965-11969.
7. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol. 2000;47:493-503.
8. Marshall V, Grosset DG. Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders. Mov Disord. 2003;18(suppl 7):S22-S27.
9. Emond P, Guilloteau D, Chalon S. PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter. CNS Neurosci Ther. 2008;14:47-64.
10. 123I-PE2I SPECT. Neuroimage. 2003;19:810-816.
11. Ziebell M, Pinborg LH, Thomsen G, et al. MRI-guided region-of-interest delineation is comparable to manual delineation in dopamine transporter SPECT quantification in patients: a reproducibility study. J Nucl Med Technol. 2010;38:61-68.
12. Pöpperl G, Radau P, Linke R, Hahn K, Tatsch K. Diagnostic performance of a 3-D automated quantification method of dopamine D2 receptor SPECT studies in the differential diagnosis of parkinsonism. Nucl Med Commun. 2005;26:39-43.
13. Mirzaei S, Zakavi R, Rodrigues M, et al. Fully automated 3D basal ganglia activity measurement in dopamine transporter scintigraphy (Spectalyzer). Ann Nucl Med. 2010;24:295-300.
14. Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med. 2005;46:1109-1118.
15. Habraken JB, Booij J, Slomka P, Sokole EB, van Royen EA. Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm. J Nucl Med. 1999;40:1091-1097.
16. 123I-IBZM uptake in the striatum applied to parkinsonism. J Nucl Med. 2000;41:220-227.
17. 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion. J Nucl Med. 2005;46:1119-1127.
18. 123I imaging. Phys Med Biol. 2006;51:N307-N311.
19. de Nijs R, Holm S, Thomsen G, Ziebell M, Svarer C. Experimental determination of the weighting factor for the energy window subtraction-based downscatter correction for I-123 in brain SPECT studies. J Med Phys. 2010;35:215-222.
20. 123I-PE2I. J Nucl Med. 2010;51:1885-1891.
21. Woods RP, Cherry SR, Mazziotta JC. Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr. 1992;16:620-633.
22. Kretschmann HJ, Weinrich W. Neuroanatomy and Cranial Computed Tomography. Stuttgart, Germany: Thieme; 1986.
23. Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal. 2001;5:143-156.
24. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27: 1533-1539.
25. Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP, Nobili F. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nucl Med Mol Imaging. 2007;34:1240-1253.